Last reviewed 2026-04-20 · How we verify

PF-06700841 45 mg (pf-06700841-45-mg)

Unknown mechanism of action

PF-06700841 45 mg, developed by Pfizer, holds a niche market position with one approved indication, though its revenue impact is unclear due to the lack of specific financial data. The drug faces strong competition from established JAK inhibitors like Baricitinib, Upadacitinib, Tofacitinib, and Ruxolitinib, each with multiple approved indications and well-defined mechanisms of action. A key risk for PF-06700841 is the requirement for a PD-L1 companion diagnostic, which may limit its patient pool and market reach. Despite these challenges, the absence of clinical trial data leaves the future pipeline outlook uncertain, highlighting the need for further development and regulatory submissions.

At a glance

Mechanism of action

Unfortunately, there is limited information available about the mechanism of PF-06700841. As a marketed drug, it is likely that the exact mechanism is not publicly disclosed. However, it is known to be used for the treatment of Multiple Sclerosis.

Approved indications

• Multiple Sclerosis

Common side effects

• COVID-19
• Urinary tract infection
• Nasopharyngitis
• Upper respiratory tract infection
• Diarrhoea
• Nausea
• Headache
• Cystitis
• Vomiting
• Blood creatine phosphokinase increased
• Fatigue
• Oral candidiasis

Drug interactions

• Warfarin
• P-glycoprotein inhibitors
• P-glycoprotein inducers
• Strong CYP3A4 inhibitors
• Strong CYP3A4 inducers
• CYP2C19 inhibitors
• CYP2C19 inducers
• CYP2D6 inhibitors
• CYP2D6 inducers
• CYP3A4 substrates
• CYP2C19 substrates
• CYP2D6 substrates

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• PF-06700841 45 mg CI brief — competitive landscape report
• PF-06700841 45 mg updates RSS · CI watch RSS
• Pfizer portfolio CI